Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,751 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Platinum-based Chemotherapy Clear all
Completed Phase 1 Interventional

Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer

NCT00575952
View directory record Official record
Conditions
Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIC Uterine Corpus Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
Interventions
Cisplatin, Doxorubicin Hydrochloride, Filgrastim, Paclitaxel, Pegfilgrastim
Drug · Biological
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
9
States / cities
Hartford, Connecticut • New Britain, Connecticut • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 15, 2026, 10:03 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

NCT02422498
View directory record Official record
Conditions
Locally Recurrent/Metastatic Triple Negative Breast Cancer
Interventions
external beam radiation therapy, cisplatin, Biopsy of Target Tumor
Radiation · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 15, 2026, 10:03 AM EDT
Recruiting Phase 1 Interventional

Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery

NCT04169763
View directory record Official record
Conditions
Stage II Vulvar Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IIIA Vulvar Cancer AJCC v8, Stage IIIB Vulvar Cancer AJCC v8, Stage IIIC Vulvar Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8
Interventions
Cisplatin, External Beam Radiation Therapy, Nelfinavir
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 15, 2026, 10:03 AM EDT
Completed Phase 2 Interventional

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

NCT00003402
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 15, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT01160744
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
IMC-1121B (ramucirumab), Pemetrexed, Carboplatin (AUC 6), Cisplatin, Gemcitabine, Carboplatin (AUC 5)
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
38
States / cities
Scottsdale, Arizona • Tucson, Arizona • Corona, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 15, 2026, 10:03 AM EDT
Not listed Phase 2 Interventional

Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00002481
View directory record Official record
Conditions
Lymphoma
Interventions
cisplatin, cyclophosphamide, cytarabine, dexamethasone, etoposide, autologous bone marrow transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
St. Luke's Medical Center
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1990
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 15, 2026, 10:03 AM EDT
Terminated Phase 1 Interventional

Cisplatin and Pemetrexed With Radiation Followed by Lobectomy

NCT01373463
View directory record Official record
Conditions
Nonsquamous Nonsmall Cell Neoplasm of Lung, Nonsmall Cell Lung Cancer Stage III
Interventions
Pemetrexed, Carboplatin, Radiation Therapy, Cisplatin, Lobectomy
Drug · Radiation · Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 90 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Oct 15, 2026, 10:03 AM EDT
Withdrawn Phase 2 Interventional

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

NCT05161533
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Carboplatin, Cisplatin, Durvalumab, Etoposide, Hypofractionated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Drug · Biological · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 15, 2026, 10:03 AM EDT
Recruiting Phase 1 Interventional

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

NCT06561685
View directory record Official record
Conditions
Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
Interventions
LY4050784, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab paclitaxel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
17
States / cities
Santa Monica, California • Aurora, Colorado • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 15, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

NCT01523587
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
afatinib, erlotinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
33
States / cities
Chandler, Arizona • La Jolla, California • Sacramento, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 15, 2026, 10:03 AM EDT
Recruiting Phase 2 Interventional

Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma

NCT07780838
View directory record Official record
Conditions
Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma, Locally Advanced Gallbladder Carcinoma, Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Ampulla of Vater Carcinoma, Metastatic Biliary Tract Carcinoma, Metastatic Extrahepatic Cholangiocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Stage III Ampulla of Vater Cancer AJCC v8, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Ampulla of Vater Cancer AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Ampulla of Vater Carcinoma, Unresectable Biliary Tract Carcinoma, Unresectable Extrahepatic Cholangiocarcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Durvalumab, Gemcitabine, Magnetic Resonance Imaging, Pemigatinib, Survey Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 15, 2026, 10:03 AM EDT
Recruiting Phase 2 Interventional

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance

NCT07594015
View directory record Official record
Conditions
Recurrent Endometrial Cancer
Interventions
Pembrolizumab, Lenvatinib
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 15, 2026, 10:03 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06236438
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Livmoniplimab, Budigalimab, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
19
States / cities
La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 15, 2026, 10:03 AM EDT
Not listed Phase 1 Interventional

Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies

NCT02433626
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Cervical Cancer, Peritoneal Cancer, Head and Neck Cancer, HNSCC, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
Interventions
COTI2, Cisplatin
Drug
Lead sponsor
Critical Outcome Technologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 15, 2026, 10:03 AM EDT
Terminated Phase 3 Interventional Results available

4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer

NCT00005047
View directory record Official record
Conditions
Bladder Cancer
Interventions
cisplatin, doxorubicin hydrochloride, methotrexate, vinblastine
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2014
U.S. locations
73
States / cities
Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 15, 2026, 10:03 AM EDT
Active, not recruiting Phase 1 Interventional

DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy

NCT05990738
View directory record Official record
Conditions
Small Cell Lung Carcinoma (SCLC)
Interventions
BI 764532, Topotecan, Single agent chemotherapy
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Jacksonville, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 15, 2026, 10:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

NCT01941316
View directory record Official record
Conditions
Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, Irinotecan Sensitive Cancers
Interventions
Carfilzomib, Irinotecan
Drug
Lead sponsor
Cancer Research and Biostatistics Clinical Trials Consortium
Network
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
Goodyear, Arizona • Lexington, Kentucky • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 15, 2026, 10:03 AM EDT
Recruiting Phase 2 Interventional

Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer

NCT06445114
View directory record Official record
Conditions
Oropharyngeal Cancer, Carcinoma
Interventions
Cisplatin
Drug
Lead sponsor
Zachary Zumsteg
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
4
States / cities
Beverly Hills, California • Los Angeles, California • Tarzana, California + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 15, 2026, 10:03 AM EDT
Completed Phase 2 Interventional

Therapy for Children With Advanced Stage High Risk Neuroblastoma

NCT00186849
View directory record Official record
Conditions
Neuroblastoma
Interventions
Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin, Peripheral Blood Stem Cell Transplant
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 20, 2009 · Synced Oct 15, 2026, 10:03 AM EDT
Recruiting Phase 3 Interventional

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

NCT07097142
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Mitomycin, Positron Emission Tomography, Survey Administration, Ultrahypofractionated Radiation Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
211
States / cities
Fort Smith, Arkansas • Irvine, California • La Jolla, California + 162 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 15, 2026, 10:03 AM EDT
Completed Phase 2 Interventional

Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Stage III or Stage IV Head and Neck Cancer

NCT00005814
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, cisplatin, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 15, 2026, 10:03 AM EDT
Recruiting Phase 2 Interventional

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

NCT04253964
View directory record Official record
Conditions
Nonsmall Cell Lung Cancer, Performance Status
Interventions
Pembrolizumab, Atezolizumab, Cemiplimab-Rwlc, Carboplatin, Paclitaxel, Nab paclitaxel, Pemetrexed, Cisplatin, Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13), QLQ-C30 Global Health/Quality of Life Questionnaire, COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes, PROMIS and FACT-G Questionnaires, Sleep Disorder Assessments (ISI, Berlin Sleep Questionnaire)
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 10:03 AM EDT
Completed Phase 2 Interventional

Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer

NCT00006004
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
13
States / cities
Atlanta, Georgia • Des Moines, Iowa • Papillion, Nebraska + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 15, 2026, 10:03 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma

NCT02641093
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Pembrolizumab, Surgery, Radiation Therapy, Cisplatin
Drug · Procedure · Radiation
Lead sponsor
Trisha Wise-Draper
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
6
States / cities
Louisville, Kentucky • Ann Arbor, Michigan • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 15, 2026, 10:03 AM EDT